Article
Oncology
Federica Ragusa, Nadia Panera, Silvia Cardarelli, Marco Scarsella, Marzia Bianchi, Stefano Biagioni, Mauro Giorgi, Anna Alisi, Mara Massimi
Summary: The study found that PDE4D gene/protein were over-expressed in HCC samples compared to normal livers, and silencing or pharmacological inhibition of PDE4D activity showed anti-tumorigenic effects by reducing cell proliferation and increasing apoptosis. Over-expression of PDE4D in human HCCs correlated with up-regulated pro-oncogenic genes, suggesting a new potential molecular network for further investigation. PDE4D depletion/inhibition may serve as a novel biomarker for diagnosis and a potential adjuvant target for HCC therapy.
Article
Biochemistry & Molecular Biology
Luhao Li, Suxin Li, Haohao Wang, Lin Li, Peiju Wang, Dongqi Shen, Xiaowei Dang
Summary: The study revealed that GSG2 is overexpressed in HCC tissues, and knockdown of GSG2 can inhibit the progression of HCC, promote cell apoptosis, and potentially participate in the oncogenesis of HCC.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Environmental Sciences
Dongqin Niu, Dong Wang, Limei Fan, Zixin Liu, Ming Chen, Weiran Zhang, Yuchen Liu, Jinhua Xu, Yunyi Liu
Summary: In this study, the effectiveness of the copper (II) complex of salicylate phenanthroline [Cu(sal)(phen)] against hepatocellular carcinoma (HCC) was investigated. Cu(sal)(phen) inhibited HCC cell proliferation and induced apoptosis by increasing mitochondrial reactive oxygen species (ROS) production. The expression of antiapoptotic proteins survivin and Bcl-2 decreased, while DNA damage marker gamma-H(2)AX and apoptotic marker cleaved PARP expression increased with Cu(sal)(phen) treatment. In vivo studies showed that Cu(sal)(phen) greatly attenuated the growth of HCC xenograft tumors. Cu(sal)(phen) was also found to be relatively safe based on toxicity experiments with mice. These findings suggest that Cu(sal)(phen) has potential as a therapeutic drug for HCC.
ENVIRONMENTAL TOXICOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Yingying Tian, Beibei Ma, Xinyue Zhao, Shiqiu Tian, Yilin Li, Hailuan Pei, Shangyue Yu, Chuang Liu, Zhaozhou Lin, Zeping Zuo, Zhibin Wang
Summary: DL extracted from Aucklandia lappa Decne. has been found to possess significant anticancer effects by suppressing the proliferation and migration of hepatocellular carcinoma (HCC) cells and inducing cell cycle arrest and apoptosis. It shows potential as a promising drug for the treatment of HCC.
ARABIAN JOURNAL OF CHEMISTRY
(2023)
Article
Virology
Baoxin Zhao, Hongxiu Qiao, Yan Zhao, Zhiyun Gao, Weijie Wang, Yan Cui, Jian Li, Zhanjun Guo, Xia Chuai, Sandra Chiu
Summary: The G1896A mutation in HBV has a dual regulatory role in exacerbating HCC severity by enhancing HBV replication, inhibiting apoptosis of hepatoma cells, and decreasing sensitivity to sorafenib.
Article
Biotechnology & Applied Microbiology
Hao Shen, Haifeng Li, Jiahua Zhou
Summary: This study found that hsa_circ_0032683 has the ability to inhibit proliferation and promote apoptosis in HCC, by competitively regulating the RTN4 gene. This provides potential therapeutic targets and biomarkers for HCC patients.
Article
Cell Biology
Ye-wei Zhang, Qian Chen, Bo Li, Hai-Yang Li, Xue-Ke Zhao, Yan-yi Xiao, Shu Liu, Shi Zuo
Summary: NAP1L1 is reported to be significantly involved in the carcinogenesis of hepatocellular carcinoma (HCC) by recruiting HDGF/c-Jun, suggesting that it acts as a potential oncogene in HCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, Research & Experimental
Yalan Deng, Liqing Lu, Xujun Liang, Jingzhi Li, Dandan Zhu, Huichao Huang, Ye Zhang, Xiangqian Zhang, Yongheng Chen, Xiaojin Liu, Ying Fu
Summary: This study reveals that NNAT is significantly downregulated in hepatocellular carcinoma (HCC), and its downregulation is associated with tumor growth and patient prognosis. The decreased expression of NNAT in HCC is induced by hypermethylation of CpG islands in the promoter region, and hypermethylation is correlated with overall survival of HCC. Moreover, NNAT overexpression inhibits HCC cell proliferation by dysregulating the PI3K-Akt signaling pathway.
Article
Cell Biology
Xiao-Wei Dang, Qi Pan, Zhen-Hai Lin, Hao-Hao Wang, Lu-Hao Li, Lin Li, Dong-Qi Shen, Pei-Ju Wang
Summary: This study confirmed that DEPDC1B knockdown restricts tumor growth in vitro and in vivo, and it interacts with CDK1, being a potential therapeutic target involved in HCC growth and progression. The results suggest that DEPDC1B plays a key role in HCC and may be a promising target for therapeutic interventions.
Article
Oncology
Chun-Ming Li, Jie Zhang, Wu Wu, Zhu Zhu, Feng Li, Di Wu, Xiao-Jun Wang, Chuan-Ming Xie, Jian-Ping Gong
Summary: This study investigated the biological function and potential mechanism of FBXO43 in hepatocellular carcinoma (HCC). The results showed that FBXO43 was upregulated in HCC patient tissues and correlated with poor clinicopathological features. Knockdown of FBXO43 inhibited HCC cell proliferation, migration, and epithelial-mesenchymal transition (EMT), which was mediated by its interaction with cyclin D1 (CCND1) and promotion of CCND1 stability. Targeting the FBXO43-CCND1 axis may provide a new potential strategy for HCC treatment.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Weiwei Liu, Lu Zheng, Rongguiyi Zhang, Ping Hou, Jiakun Wang, Linquan Wu, Jing Li
Summary: High expression of circ-ZEB1 and PIK3CA is associated with poor prognosis in HCC. Circ-ZEB1 promotes the expression of PIK3CA by silencing miR-199a-3p, affecting HCC proliferation and apoptosis.
Article
Oncology
Yan-hui Wu, Bin Yu, Jiang-min Zhou, Xue-han Shen, Wei-xun Chen, Xi Ai, Chao Leng, Bin-yong Liang, Ya-jie Shao
Summary: This study aimed to investigate the relationship between metastatic human hepatocellular carcinoma (HCC) and the dysregulation of MicroRNA-188-5p (miR-188) by using cell lines. The results showed that miR-188 was decreased in metastatic HCC cells compared to normal hepatic cells and non-invasive cell lines. Furthermore, it was found that miR-188 inhibits the proliferation and migration of metastatic HCC cells by targeting FOXN2.
Article
Pharmacology & Pharmacy
Gaopan Dong, Xiaohan Ye, Shumei Wang, Wenhua Li, Rong Cai, Lupei Du, Xiaodong Shi, Minyong Li
Summary: This study reports a novel TrxR inhibitor Au-24 and its inhibitory ability to hepatocellular carcinoma in vitro and in vivo. Au-24 suppresses the proliferation of HepG2 cells through regulating multiple signaling pathways and inducing oxidative stress. In vivo experiments demonstrate that Au-24 is more effective than the traditional drug AA1 in inhibiting tumor growth.
PHARMACOLOGICAL RESEARCH
(2022)
Article
Immunology
Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Yuxian Bai, Aibing Xu, Meili Sun, Wei Wang, Jian Wu, Ming Huang, Lijie Song, Luke Huang, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Bai
Summary: This study evaluated the efficacy and safety of the combination therapy of cadonilimab plus lenvatinib for advanced hepatocellular carcinoma. The results demonstrated promising efficacy and manageable toxicity, suggesting it as a potential treatment option in the first-line setting for aHCC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Xia-Hui Lin, Dan-Ying Zhang, Zhi-Yong Liu, Wen-qing Tang, Rong-Xin Chen, Dong-ping Li, Shuqiang Weng, Ling Dong
Summary: The lncRNA-AC079061.1/VIPR1 axis was identified as a novel biomarker that inhibited the proliferation and invasion of hepatocellular carcinoma, affecting the ultimate disease outcome.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Pathology
Xiaobo Zhang, Chen Wang, Danhua Shen
Summary: This study investigated the Clinicopathological features and FH mutation in FH-dUL. FH-dUL is rare and the combination of predictive Clinicopathological evaluation, FH and 2SC IHC test, and molecular test were helpful for the screening of FH-dUL or even HLRCC.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Review
Pathology
Gaurav Dubey, Mithilesh Singh, Himmat Singh, Mohit Agarwal, Shailendra Singh Chandel, Anurag Mishra, Ravindra Pal Singh, Neelima Kukreti
Summary: SnoRNAs play a crucial role in autoimmune diseases, influencing gene expression, immune cell development, and immune regulation. They have the potential to be biomarkers or therapeutic targets for disease management. However, further research is needed to elucidate their precise molecular mechanisms.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
P. Suhaj, D. Do, T. Olejar, R. Pichova, O. Lang, R. Matej
Summary: Pancreatic polypeptide cell hyperplasia (PPY-H) is a multiplication of neuroendocrine cells producing pancreatic polypeptide (PPY). The development and role of PPY-H still need to be further elucidated. This study analyzed 12 cases of PPY-H accompanying pancreatic neuroendocrine neoplasias (NEN) and found that gastrointestinal symptoms may be more related to PPY-H rather than NEN hormonal production. Strong SSTR2 expression in PPY-H suggests the potential utility of radiotracers in clinical diagnostics, but further studies are needed.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
Ruyun Zhang, Xiaofei Liao, Bin Zhang, Xiaohong Huang, Guanjie Qin, Xiangyun Kong, Yuan Xie, Yunyan Mo, Jinxuan Dai, Chunqiao Gan, Zan Luo, Jingyan Lu, Wei Jiang
Summary: This study found that patients with high COV+TIL score had worse prognosis in nasopharyngeal carcinoma.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Review
Pathology
Waleed Hassan Almalki
Summary: Understanding the molecular pathways behind cardiovascular illnesses is crucial. Recent studies have revealed the role of Xist RNA in cardiovascular diseases, including epigenetic changes, gene expression, cellular identity, and sex chromosomal inactivation. Dysregulation of Xist RNA expression is associated with conditions such as atherosclerosis, hypertrophy, and cardiac fibrosis.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
Yanxin Dong, Boshi Fan, Mingyang Li, Jiale Zhang, Shun Xie, Shouyin Dia, Qingge Jia, Taiqian Gong
Summary: Tescalcin (TESC) is upregulated in esophageal squamous carcinoma (ESCC) and is associated with poor prognosis, tumor infiltration, staging, and lymph node metastasis. TESC promotes proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) progression in ESCC, as well as activates the AKT pathway. TESC may serve as a prognostic factor and provide a new therapeutic strategy for ESCC.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
Ozge Sukruoglu Erdogan, Demet Akdeniz Odemis, Zubeyde Yalniz Kayim, Orkun Gurbuz, Seref Bugra Tuncer, Seda Kilic, Betul Celik, Samuray Tuncer, Sema Buyukkapu Bay, Rejin Kebudi, Hulya Yazici
Summary: This study found that methylation of the RB1 gene promoter does not influence the hereditary transmission of familial retinoblastoma.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Review
Pathology
Syam Mohan, Mohammed Ageeli Hakami, Hamad Ghaleb Dailah, Asaad Khalid, Asim Najmi, Khalid Zoghebi, Maryam A. Halawi, Thaifallah Munahi Alotaibi
Summary: Cancer is a complex disease caused by multiple factors, and miR-155 plays a significant role as a regulator of the NF-kappa B signaling pathway, contributing to cancer development and progression.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
